Cidara's Flu Drug: A Phase 2 Triumph, A Phase 3 Gauntlet

Cidara Therapeutics surged 250% on strong CD388 trial results and solid financials, but faces Phase 3 challenges ahead. See ...

Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute ...

The Company has submitted a supplemental New Drug Application (sNDA) seeking the approval of revumenib for the treatment of R/R mNPM1 AML. The sNDA has been granted Priority Review by the FDA and ...
Barchart on MSN

Use ADX to Find Stronger Trade Setups and Avoid Getting Whipsawed by Weak Stock Trends

Most traders focus on finding entries — but avoiding bad trades is just as important. That’s where the Average Directional Index (ADX) comes in. In this clip from his recent live Barchart webinar, ...
storage.googleapis.com on MSN

Use ADX to Find Stronger Trade Setups | How to Avoid Getting Whipsawed by Weak Stock Trends

Most traders focus on finding entries — but avoiding bad trades is just as important. That’s where the Average Directional Index (ADX) comes in. In a live Barchart webinar, John Rowland, CMT, ...

Atlassian’s $1B DX Deal To Measure AI -Driven Development

Atlassian acquires developer analytics firm DX for $1 billion to help enterprises measure AI investment returns in software ...

Nanobiotix: Today's Data Readout For Radiation Therapy Enhances Bull Case

Nanobiotix S.A. stock surges on promising cancer trial results and major partnership. Click for more on NBTX stock and why ...